In 2025, Ionis Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Ionis Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 2,615a | 2,616a | 2,695a | |
Total Scope 2 | ||||
Market-Based | 3,133a | 2,530a | 2,788a | |
Location-Based | N/A | N/A | N/A | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 2.771a | 3.7099a | 3.4216a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals amounted to 5,748 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals increased by 11.7%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Ionis Pharmaceuticals were 2,615 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Ionis Pharmaceuticals's Scope 1 emissions have increased by 1.91%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2024), Ionis Pharmaceuticals's Scope 1 emissions remained relatively stable, indicating that Ionis Pharmaceuticals's emissions have plateaued with no significant change in its operational footprint.a
In 2025, Ionis Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 3,133 tCO₂e using the market-based method.a
Since 2021, Ionis Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have increased by 52.68%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2024), Ionis Pharmaceuticals's Scope 2 emissions (Market-Based) rose by 23.83% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, Ionis Pharmaceuticals reported its Scope 2 emissions using the market-based method.a
In 2025, Ionis Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 2,615 tCO₂e and total revenues of USD 944 millions. This translates into an emissions intensity of 2.77 tCO₂e per millions USD.a
In 2025, Ionis Pharmaceuticals reported a Scope 1 emissions intensity of 2.77 tCO₂e per millions USD. Compared to the peer group median of 2.76, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, Ionis Pharmaceuticals ranked 12 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Ionis Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a